Previous 10 | Next 10 |
BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ): For more detail related to the fiscal year 2021 unaudited second quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and su...
BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ): For more detail related to the fiscal year 2021 unaudited first quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and sub...
A major objective of a COVID-19 vaccine is to prevent severe disease onset in SARS-CoV-2 infected people. Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, and colleagues, including members of the staff at BIOQUAL, showed in recently published previous w...
BIOQUAL ((OTC Pink: BIOQ) ( www.bioqual.com ): BIOQUAL’s Board of Directors has declared a dividend of $1.10 per share for shareholders of record on September 28, 2020, payable on October 21, 2020. This is the nineteenth dividend declared by BIOQUAL. Statements herein that are no...
BIOQUAL announces the publication of the successful testing of an mRNA vaccine in non-human primates. The candidate vaccine, mRNA-1273, was co-developed by scientists at the NIAID Vaccine Research Center and a pharmaceutical company. The animal studies were performed at BIOQUAL. The results w...
BIOQUAL announces the publication of the successful testing of a candidate vaccine in non-human primates. A group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in...
BIOQUAL announces the release of two research publications in Science Magazine of our non-human primate model development efforts and our first successful testing of a COVID-19 vaccine candidate. These publications show that an infection in macaques can protect from reinfection and that immun...
BIOQUAL announces the development of programs for in-vivo testing of COVID-19 candidate vaccines. BIOQUAL’s efforts to develop animal models for COVID-19 began in February 2020 in collaboration with Dr. Dan Barouch at Beth Israel Deaconess Medical Center and the Ragon Institute, both a...
BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ): For more detail related to the fiscal year 2020 unaudited second quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and subject to ris...
BIOQUAL, Inc. (OTC Pink: BIOQ) ( www.bioqual.com ): For more detail related to the fiscal year 2020 unaudited first quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and subject to risk...
News, Short Squeeze, Breakout and More Instantly...
BIOQUAL, Inc. (OTC Pink: BIOQ) www.bioqual.com : For more detail related to the fiscal year 2024 unaudited third quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and subjec...
Guardforce AI Co. Limited (GFAI) is expected to report for quarter end 2023-12-31 Bright Scholar Education Holdings Limited American Depositary Shares each representing four Class A (BEDU) is expected to report for quarter end 2024-02-29 Schlumberger N.V. (SLB) is expected to report $0.74...
BIOQUAL, Inc. (OTC Pink: BIOQ) www.bioqual.com : For more detail related to the fiscal year 2024 unaudited second quarter results, please visit our web site at www.bioqual.com . Statements herein that are not descriptions of historical facts are forward-looking and subje...